Hs 766THomo sapiens (Human)Cancer cell line
Also known as: Hs 766.T, HS-766T, Hs-766T, HS 766T, HS-766-T, Hs-766-T, HS766T, Hs766T, H766T, 766T, Hs 766, Hs-776-T
Hs766T
Quick Overview
Pancreatic cancer cell line with known genetic alterations and metastatic potential.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0334 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
| Age | 64 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Pancreatic adenocarcinoma |
|---|---|
| Lineage | Pancreas |
| Subtype | Pancreatic Adenocarcinoma |
| OncoTree Code | PAAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000178_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | SMAD4 | - | Homozygous | - | from parent cell line BxPC-3 |
| MutationSimple | KRAS | p.Gln61His (c.183A>C) | Heterozygous | 1 of 3 alleles | Unknown, PubMed=8426738 |
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis.
Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.
J. Proteomics Bioinformatics 2:1-18(2009).
Epithelial cell cultures from normal and cancerous human tissues.";
Owens R.B., Smith H.S., Nelson-Rees W.A., Springer E.L.
J. Natl. Cancer Inst. 56:843-849(1976).
In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue.
Smith H.S.
J. Natl. Cancer Inst. 62:225-230(1979).
Nuclear ultrastructure of epithelial cell lines derived from human carcinomas and nonmalignant tissues.
Smith H.S., Springer E.L., Hackett A.J.
Cancer Res. 39:332-344(1979).
Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes.
Klein-Szanto A.J.P.
Oncogene 7:1503-1511(1992).
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Gershwin M.E., Lentz D., Owens R.B.
Exp. Cell Biol. 52:361-370(1984).
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer.
Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.
Int. J. Cancer 58:185-191(1994).
Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.
Meltzer P.S., Ried T.
Am. J. Pathol. 154:525-536(1999).
Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.
Chaloupka B., Deiss Y., Simon B., Schudy A.
Cancer Lett. 139:43-49(1999).
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Int. J. Cancer 91:350-358(2001).
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
Kern S.E., Goggins M.G., Hruban R.H.
Cancer Res. 63:8614-8622(2003).
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Veltman J.A., van Kessel A.G., Hoglund M.
Cancer Res. 64:3052-3059(2004).
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
Hirohashi S.
Pancreas 29:193-203(2004).
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Oncogene 24:1794-1801(2005).
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Kern S.E.
Cancer Res. 66:7920-7928(2006).
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Cancer Sci. 99:986-994(2008).
Hybrids of aneuploid human cancer cells permit complementation of simple and complex cancer defects.
Chakravarti A., Kern S.E.
Cancer Biol. Ther. 8:347-355(2009).
Phenotype and genotype of pancreatic cancer cell lines.";
Scaife C.L., Firpo M.A., Mulvihill S.J.
Pancreas 39:425-435(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Linnartz R., Zubel A., Slamon D.J., Finn R.S.
Br. J. Cancer 111:1788-1801(2014).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Biankin A.V., Wu J.-M., Daly R.J.
Mol. Cell. Proteomics 15:2671-2685(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).